Faculty
Oncology Division
Alphabetical list (active faculty):   
Jeffrey P. Ward

Jeffrey P. Ward, MD, PhD

Assistant Professor

Department of Medicine

Oncology Division

Medical Oncology

Clinical Interests

  • Thoracic malignancies

Research Interests

  • Tumor Immunology
  • Neoantigens
  • Immunotherapy

Contact

  • 314-747-7409 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0021-09
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 9934 Wohl Clinic (office)
  • 9934 Wohl Clinic (lab)

Peer-reviewed Manuscripts

  • Genomic Profiling of Lung Adenocarcinoma in Never-Smokers
    Devarakonda S, Li Y, Martins Rodrigues F, Sankararaman S, Kadara H, Goparaju C, Lanc I, Pepin K, Waqar SN, Morgensztern D, Ward J, Masood A, Fulton R, Fulton L, Gillette MA, Satpathy S, Carr SA, Wistuba I, Pass H, Wilson RK, Ding L, Govindan R
    J Clin Oncol 2021 Nov 20;39(33):3747-3758
  • Phase I/Dose Expansion Trial of Brentuximab Vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ward J, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL
    Blood 2021 Nov 15; [Epub ahead of print]
  • Bcl6-Independent in Vivo Development of Functional Type 1 Classical Dendritic Cells Supporting Tumor Rejection
    Bagadia P, O'Connor KW, Wu R, Ferris ST, Ward JP, Schreiber RD, Murphy TL, Murphy KM
    J Immunol 2021 Jun 16; [Epub ahead of print]
  • Radiation-Induced Neoantigens Broaden the Immunotherapeutic Window of Cancers With Low Mutational Loads
    Lussier DM*, Alspach E*, Ward JP*, Miceli AP, Runci D, White JM, Mpoy C, Arthur CD, Kohlmiller HN, Jacks T, Artyomov MN, Rogers BE, Schreiber RD (*contributed equally)
    Proc Natl Acad Sci U S A 2021 Jun 15;118(24)
  • Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
    Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng AHC, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC, Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA
    Tumor Neoantigen Selection Alliance

    Cell 2020 Oct 29;183(3):818-834e13
  • CDC1 Prime and Are Licensed by CD4(+) T Cells to Induce Anti-Tumour Immunity
    Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT 4th, Bagadia P, Liu T, Briseno CG, Li L, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM
    Nature 2020 Aug;584(7822):624-629
  • MHC-II Neoantigens Shape Tumour Immunity and Response to Immunotherapy
    Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD
    Nature 2019 Oct;574(7780):696-701
  • Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
    Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D
    Clin Cancer Res 2019 Oct 15;25(20):6119-6126
  • High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling During Successful Immune-Checkpoint Cancer Therapy
    Gubin MM*, Esaulova E*, Ward JP*, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN (*contributed equally)
    Cell 2018 Nov 15;175(5):1443
  • Checkpoint Blockade Immunotherapy Reshapes the High-Dimensional Phenotypic Heterogeneity of Murine Intratumoural Neoantigen-Specific CD8(+) T Cells
    Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW
    Nat Commun 2017 Sep 15;8(1):562
  • Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
    Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber RD
    Cancer Immunol Res 2017 Feb;5(2):106-117
  • CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes With NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells
    Davis ZB, Sowrirajan B, Cogswell A, Ward JP, Planelles V, Barker E
    AIDS Res Hum Retroviruses 2017 Feb;33(2):93-100
  • Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach
    Johanns TM*, Ward JP*, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP (*contributed equally)
    Cancer Immunol Res 2016 Dec;4(12):1007-1015
  • Understanding the Molecular Manipulation of DCAF1 by the Lentiviral Accessory Proteins Vpr and Vpx
    Cassiday PA, DePaula-Silva AB, Chumley J, Ward J, Barker E, Planelles V
    Virology 2015 Feb;476:19-25
  • Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
    Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD
    Nature 2014 Nov 27;515(7528):577-81
  • Preparation and Use of HIV-1 Infected Primary CD4+ T-Cells as Target Cells in Natural Killer Cell Cytotoxic Assays
    Davis ZB, Ward JP, Barker E
    J Vis Exp 2011 Mar 14;(49) pii: 2668
  • Degranulation of Natural Killer Cells Following Interaction With HIV-1-Infected Cells Is Hindered by Downmodulation of NTB-A by Vpu
    Shah AH, Sowrirajan B, Davis ZB, Ward JP, Campbell EM, Planelles V, Barker E
    Cell Host Microbe 2010 Nov 18;8(5):397-409
  • HIV-1 Vpr Triggers Natural Killer Cell-Mediated Lysis of Infected Cells Through Activation of the ATR-Mediated DNA Damage Response
    Ward J, Davis Z, DeHart J, Zimmerman E, Bosque A, Brunetta E, Mavilio D, Planelles V, Barker E
    PLoS Pathog 2009 Oct;5(10):e1000613
  • Lysis of Endogenously Infected CD4+ T Cell Blasts by RIL-2 Activated Autologous Natural Killer Cells From HIV-Infected Viremic Individuals
    Fogli M, Mavilio D, Brunetta E, Varchetta S, Ata K, Roby G, Kovacs C, Follmann D, Pende D, Ward J, Barker E, Marcenaro E, Moretta A, Fauci AS
    PLoS Pathog 2008 Jul 11;4(7):e1000101
  • HIV Modulates the Expression of Ligands Important in Triggering Natural Killer Cell Cytotoxic Responses on Infected Primary T-Cell Blasts
    Ward J, Bonaparte M, Sacks J, Guterman J, Fogli M, Mavilio D, Barker E
    Blood 2007 Aug 15;110(4):1207-14
  • Regulation of CD4 Expression Via Recycling by HRES-1/RAB4 Controls Susceptibility to HIV Infection
    Nagy G, Ward J, Mosser DD, Koncz A, Gergely P Jr, Stancato C, Qian Y, Fernandez D, Niland B, Grossman CE, Telarico T, Banki K, Perl A
    J Biol Chem 2006 Nov 10;281(45):34574-91
  • HLA-C and HLA-E Reduce Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity of HIV-Infected Primary T Cell Blasts
    Ward JP, Bonaparte MI, Barker E
    AIDS 2004 Sep 3;18(13):1769-79

Invited Publications